Plain-English translation of NCT03732638 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial studied whether , a new preventive medication, could reduce the number of migraine days people experienced each month. Researchers compared this medication to a placebo (a dummy pill with no active ingredient) over 12 weeks, then continued to follow participants who wanted to keep taking the medication for an additional year. The goal was to see if taking this treatment every other day could help prevent migraines from happening as frequently.
Many people suffer from frequent migraines that interfere with their daily lives, and current preventive treatments don't work well for everyone. This trial was designed to test whether this new medication could offer another option for people looking to reduce how often their migraines occur.
Participants took either the study medication or a placebo pill every other day for 12 weeks, while keeping a record of their migraine days. Those who benefited and met study requirements could continue taking the medication for an additional 52 weeks. If participants had a migraine on a non-scheduled day, they could take an extra dose to treat it. The trial included follow-up visits to check safety and collect information about how the treatment was working.
AI-generated summary from trial data · Sep 21, 2026 · Not medical advice
United States